drugset / Trial / NCT07289750

The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD

NCT07289750

RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the efficacy and safety of the combination of alogliptin and actoplus met with that of actoplus met alone in improving the glucose and lipid metabolism and pancreatic function in T2DM patients complicated with MAFLD.

Timeline

Start
2026-05-01
Primary completion
2027-08-31
Completion
2027-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Alogliptin Unknown
Comparator Metformin Small molecule
Comparator Pioglitazone Small molecule